TRVI β€” TREVI THERAPEUTICS INC

Ownership history in Frazier Life Sciences Management, L.P.  Β·  15 quarters on record

AI Ownership Summary

Frazier Life Sciences Management, L.P. reported TREVI THERAPEUTICS INC (TRVI) in 15 quarterly 13F filings from 2023 Q3 through 2025 Q4. Peak portfolio weight reached 3.45% in 2025 Q4. The latest visible filing shows TRVI at 3.45% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this TRVI ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Frazier Life Sciences Management, L.P.'s position in TREVI THERAPEUTICS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

TRVI was reported at 3.45% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
3.45% in 2025 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q3 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How Frazier Life Sciences Management, L.P. held TRVI β€” position size vs. price
% of Fund (quarterly)    TRVI price (quarter-end, indexed to 100)
πŸ“‹ Quarterly Holdings History 10 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 UNCHANGED 10,259,409 β€” 0% 3.45% $128.4M 2026-02-14 (Est.) $10.40
2025 Q3 UNCHANGED 10,259,409 β€” 0% 2.81% $93.9M 2025-11-14 $11.37
2025 Q2 UNCHANGED 10,259,409 β€” 0% 2.24% $56.1M 2025-08-14 $7.49
2025 Q1 REDUCED 10,259,409 -405,365 -3.8% 2.95% $64.5M 2025-05-15 $6.19
2024 Q4 ADDED 10,664,774 +3,283,684 +44.5% 1.82% $43.9M 2025-02-18 $4.22
2024 Q3 UNCHANGED 7,381,090 β€” 0% 0.99% $24.7M 2024-11-15 $2.75
2024 Q2 UNCHANGED 7,381,090 β€” 0% 1.03% $22.0M 2024-08-15 $2.75
2024 Q1 UNCHANGED 7,381,090 β€” 0% 1.07% $25.5M 2024-05-15 $2.77
2023 Q4 ADDED 7,381,090 +500,000 +7.3% 0.53% $9.9M 2024-02-14 $2.12
2023 Q3 UNCHANGED 6,881,090 β€” 0% 1.00% $15.0M 2023-11-14 $1.43
5 older quarters hidden  β€”  Sign in free or upgrade to Premium to see full history

FAQ About Frazier Life Sciences Management, L.P. and TRVI

These are the practical questions this page is built to answer before you even open the full history table.

How long has Frazier Life Sciences Management, L.P. reported owning TRVI?

Frazier Life Sciences Management, L.P. reported TRVI across 10 quarterly 13F filings, from 2023 Q3 through 2025 Q4.

What was the largest reported TRVI position in Frazier Life Sciences Management, L.P.'s portfolio?

The largest reported portfolio weight for TRVI was 3.45% in 2025 Q4.

What is the latest reported TRVI position on this page?

The most recent filing on this page is 2025 Q4, when Frazier Life Sciences Management, L.P. reported 10,259,409 shares, equal to 3.45% of portfolio, with an estimated market value of $128.4M.

What does the chart on this TRVI ownership page compare?

The chart compares Frazier Life Sciences Management, L.P.'s quarterly TRVI portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

← Back to Frazier Life Sciences Management, L.P. Holdings